NIH PAR · NIDA · R21
PAR-25-101: Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant…
- NOFO number
- PAR-25-101
- Type
- PAR
- Activity code
- R21
- Primary institute
- NIDA · National Institute on Drug Abuse
- Clinical trials
- Optional
- Posted
- Dec 30, 2024
- Opens
- Feb 10, 2025
- Expires
- Aug 12, 2027
PAR-25-101 due dates
2 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| March 10, 2025 | March 10, 2025 | March 10, 2025 | July 2025 | October 2025 | December 2025 |
| August 12, 2025 | August 12, 2025 | August 12, 2025 | November 2025 | January 2026 | April 2026 |
| March 10, 2026 | March 10, 2026 | March 10, 2026 | July 2026 | October 2026 | December 2026 |
| August 05, 2026 | August 05, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| March 10, 2027 | March 10, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| August 11, 2027 | August 11, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
Projects funded under PAR-25-101
NIH RePORTER lists 2 projects funded under PAR-25-101 in FY2022–FY2026, with $696K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$696K
Award dollars under PAR-25-101, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 2 | 2 | $696K |
Institutions with the most funding
- Weill Medical Coll of Cornell Univ$466K · 1 project
- Tulane University of Louisiana$230K · 1 project
Funding institutes
- NIDA$696K · 2
Activity codes funded
- R212 records
Most recent new awards
- A novel RNA-based neuromodulation tool to treat chronic pain and reduce opioid dependence (opens NIH RePORTER)
Weill Medical Coll of Cornell Univ · 1R21DA066282-01 · NIDA · Notice Aug 28, 2026
$466KR21
- Novel Mechanisms of Protection from Substance Abuse Drugs (opens NIH RePORTER)
Tulane University of Louisiana · 1R21DA065065-01 · NIDA · Notice Apr 27, 2026
$230KR21
What its predecessor PAR-21-208 funded
PAR-25-101 reissues PAR-21-208. Its funding history is the best guide to who wins under this program: 20 projects and $8.1M in FY2022–FY2026.
Projects funded
20
Distinct projects, FY2022–FY2026
New awards
20
Type 1 (new project) award records
NIH funding
$8.1M
Award dollars under PAR-21-208, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 2 | 2 | $435K |
| FY2023 | 11 | 9 | $2.4M |
| FY2024 | 14 | 5 | $2.9M |
| FY2025 | 7 | 4 | $2.3M |
| FY2026 | 0 | 0 | $0 |
Institutions with the most funding
- University of California, San Diego$869K · 2 projects
- Yale University$818K · 2 projects
- Brigham and Women's Hospital$471K · 1 project
- Albert Einstein College of Medicine$462K · 1 project
- University of Pennsylvania$454K · 1 project
- University of Texas Med Br Galveston$440K · 1 project
- Stanford University$437K · 1 project
- University of California Los Angeles$429K · 1 project
Funding institutes
- NIDA$8.1M · 34
Activity codes funded
- R2134 records
Most recent new awards
- Device-free, long-term monitoring of opioid circuit activity in individual mice exposed to fentanyl (opens NIH RePORTER)
University of Pennsylvania · 1R21DA062242-01A1 · NIDA · Notice Jul 9, 2025
$454KR21
- GPR6: A Circuit-Level Druggable Target in Cocaine Use Disorder (opens NIH RePORTER)
University of Texas Med Br Galveston · 1R21DA063306-01 · NIDA · Notice Jul 3, 2025
$440KR21
- Genetic analysis of psychoplasticity in C. elegans (opens NIH RePORTER)
University of Oregon · 1R21DA060522-01A1 · NIDA · Notice Jun 11, 2025
$406KR21
- Finding the missing parts of human genetics of substance use disorders (opens NIH RePORTER)
Yale University · 1R21DA063120-01 · NIDA · Notice May 29, 2025
$358KR21
- Validating a novel chemogenetic strategy for opioid use disorder (opens NIH RePORTER)
Albert Einstein College of Medicine · 1R21DA057695-01A1 · NIDA · Notice Mar 19, 2024
$252KR21
- Studying synaptic transmission under opioid exposure using hiPSC-derived midbrain model and hyperspectral fluorescence lifetime imaging (opens NIH RePORTER)
University of Texas at Austin · 1R21DA060543-01 · NIDA · Notice Mar 13, 2024
$222KR21
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-101. Contact the program officer at the institute that fits your research before applying.
- NIDA · National Institute on Drug Abuse
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy.
Notices of Special Interest (NOSIs)
NIH has attached 8 NOSIs to PAR-25-101; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
-  The combined budget for direct costs for the two year project period may not exceed 275,000. No more than 150,000 in direct costs may be requested in any single year.
- Project period
- The maximum project period is 2 years.       NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-21-208.
Other open NOFOs for R21
- RFA-DA-26-056Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)NIDA · next due Dec 3, 2026
- PA-25-304NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)NIH · next due Oct 16, 2026
- PA-25-306NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)NIH · next due Oct 16, 2026
- PAR-25-143Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)NCI · next due Oct 16, 2026
- PAR-25-369Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)NHGRI · next due Oct 20, 2026
- RFA-MH-27-125Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)NIMH · next due Nov 9, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.